SATB1 and breast carcinoma: However, there are also contradictory results even in the same tumor types that the best example can be breast cancer [72, 78], suggesting that the discrepancy may reflect differences in experimental design (e.g., antibody clones, or measuring the transcript level of SATB1 in whole tumor tissue samples vs. scoring the level of SATB1 protein in particular cells, with an emphasis on its subcellular location) and scoring systems and the subjectivity of the pathologists' interpretation.